The FDA just approved Eli Lilly's Zepbound for sleep apnea — and Medicare coverage could be next
Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug ...
STAT37m
Eli Lilly’s obesity drug Zepbound approved to treat sleep apnea in U.S.
The FDA has cleared Eli Lilly’s obesity drug Zepbound as the first treatment for obstructive sleep apnea in the U.S.
FiercePharma1h
Lilly's Zepbound scores 2nd approval with landmark FDA nod in obstructive sleep apnea
Christmas has come early for Eli Lilly this year, courtesy of a fresh FDA approval for the Indianapolis drugmaker’s obesity ...
Zepbound Approved For Sleep Apnea
An estimated 39 million American adults suffer from obstructive sleep apnea, a condition in which the upper airway is blocked ...
Becker's Hospital Review1h
FDA: No more need for compounded versions of Mounjaro, Zepbound
The FDA has declared the end of the two-year shortages of Eli Lilly's Mounjaro and Zepbound — used to treat diabetes and weight loss, respectively — and has reaffirmed its decision to halt the ...
STAT9d
Eli Lilly strikes Zepbound deal with Ro, amid questions about future of compounded GLP-1s
Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.
Novo's next-gen obesity drug candidate trial disappoints
Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped overweight patients cut their ...